• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis
CONCLUSIONS: We found moderate- to high-certainty evidence that donepezil 5 mg, donepezil 10 mg, and galantamine have a slight beneficial effect on cognition in people with VCI, although the size of the change is unlikely to be clinically important. Donepezil 10 mg and galantamine 16 to 24 mg are probably associated with more adverse events than placebo. The evidence for rivastigmine was less certain. The data suggest that donepezil 10 mg has the greatest effect on cognition, but at the cost of adverse effects. The effect is modest, but in the absence of any other treatments, people living with VCI may still wish to consid...
Source: Cochrane Database of Systematic Reviews - March 11, 2021 Category: General Medicine Authors: Ceri E Battle Azmil H Abdul-Rahim Susan D Shenkin Jonathan Hewitt Terry J Quinn Source Type: research

Review: Cholinesterase inhibitors do not reduce progression to dementia from mild cognitive impairment.
CONCLUSION In adults with mild cognitive impairment, cholinesterase inhibitors do not differ from placebo for progression to dementia at 1 and 3 years but increase nonserious adverse events.Cholinesterase inhibitors (ChEIs) vs placebo in adults with mild cognitive impairment*OutcomesNumber of trials (n)Weighted event ratesAt 16 wk to 3 yChEIsPlaceboRRR (95% CI)NNT (CI)Dementia at 1 y3 (2560)7.6%12%31% (0 to 53)NSDementia at 2 y2 (2048)12%18%33% (17 to 45)17 (12 to 34)Dementia at 3 y2 (1530)20%24%16% (-2 to 30)NSSerious adverse events6 (4207)19%19%3% (-10 to 14)NSRRI (CI)NNH (CI)Any adverse event6 (4207)89%82%9% (2 to 16)15...
Source: Annals of Internal Medicine - February 19, 2013 Category: Internal Medicine Authors: Masoodi N Tags: Ann Intern Med Source Type: research